Table 15.11
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1998 to 2003
Recipients with Liver Transplants

	Transplant Year					
	1998	1999	2000	2001	2002	2003
Transplants	4,516	4,751	4,995	5,190	5,331	5,672
Functioning Graft at 2 Years PostTx	3,213	3,371	3,680	3,812	3,991	4,222
With Maintenance Use Recorded at 2 Years PostTx	2,982	3,180	3,617	3,723	3,868	4,109
--- + MMF/MPA	0.1%	0.1%	0.1%	0.2%	0.3%	0.5%
--- + MMF/MPA + Siro/Evero	0.0%	0.2%	0.4%	0.6%	1.2%	1.8%
--- + MMF/MPA + Steroids	0.5%	0.2%	0.3%	0.3%	0.3%	0.4%
--- + OtherAntimet	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + OtherAntimet + Siro/Evero	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%
--- + OtherAntimet + Steroids	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.1%	0.4%	1.4%	2.0%	2.6%	2.9%
--- + Siro/Evero + Steroids	0.2%	0.2%	0.4%	0.7%	1.1%	0.9%
--- + Steroids	0.9%	0.9%	0.4%	0.6%	0.6%	0.4%
CyA	6.8%	6.6%	5.0%	4.4%	3.1%	2.4%
CyA + MMF/MPA	2.8%	2.7%	2.2%	2.4%	1.8%	2.4%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%
CyA + MMF/MPA + Steroids	4.0%	3.6%	2.5%	1.6%	1.6%	1.2%
CyA + OtherAntimet	0.8%	0.6%	0.6%	0.2%	0.1%	0.3%
CyA + OtherAntimet + Steroids	2.5%	1.7%	0.9%	0.3%	0.2%	0.2%
CyA + Siro/Evero	0.4%	0.3%	0.7%	0.5%	0.3%	0.4%
CyA + Siro/Evero + Steroids	0.2%	0.2%	0.4%	0.2%	0.1%	0.3%
CyA + Steroids	10.3%	6.9%	3.6%	2.2%	1.6%	1.3%
Tac	29.1%	34.3%	38.2%	40.2%	39.9%	37.9%
Tac + MMF/MPA	4.8%	6.2%	7.6%	9.8%	12.2%	16.0%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
Tac + MMF/MPA + Siro/Evero	0.0%	0.0%	0.2%	0.2%	0.4%	0.3%
Tac + MMF/MPA + Steroids	6.2%	6.9%	7.0%	8.2%	8.8%	9.4%
Tac + OtherAntimet	1.3%	0.5%	0.6%	0.6%	1.0%	1.0%
Tac + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + OtherAntimet + Steroids	1.6%	1.3%	1.0%	1.2%	0.9%	0.5%
Tac + Siro/Evero	0.3%	0.8%	2.5%	3.1%	2.5%	2.6%
Tac + Siro/Evero + Steroids	0.6%	1.1%	1.9%	1.6%	2.1%	1.2%
Tac + Steroids	23.8%	20.8%	17.9%	15.8%	15.4%	13.8%
Other Regimen	2.5%	3.4%	4.0%	2.8%	2.0%	1.8%

Source: OPTN/SRTR Data as of May 1, 2006.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.